| 1 |
Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions.[J]. Mayo Clinic Proceedings, 2008, 83(2): 235.
|
| 2 |
施焕中，张予辉. 《恶性胸腔积液诊断与治疗专家共识》解读[J]. 中华医学信息导报，2014, 29(9): 18.
|
| 3 |
Lombardi G, Zustovich F, Nicoletto MO, et al. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches.[J]. American Journal of Clinical Oncology, 2010, 33(4): 420-423.
|
| 4 |
Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010[J]. Thorax, 2010, 65(Suppl 2): ii32.
|
| 5 |
G. Fbuthe, J. Sistermanns. Recombinant Tumour Necrosis Factor in the Local Therapy of Malignant Pleural Effusion[J]. Eur J Cancer, 1997, 33(2): 226-231.
|
| 6 |
Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions[J]. Current Opinion in Pulmonary Medicine, 2005, 11(4): 296.
|
| 7 |
Zarogoulidis P, Chatzaki E, Hohenforst-Schmidt W, et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: A case series and literature review[J]. Cancer Gene Therapy, 2012, 19(9): 593-600.
|
| 8 |
Qureshi RA, Collinson SL, Powell RJ, et al. Management of Malignant Pleural Effusion Associated with Trapped Lung Syndrome[J]. Asian Cardiovascular & Thoracic Annals, 2008, 16(2): 120-123.
|
| 9 |
Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management[J]. Lung Cancer, 2006, 54(1): 1-9.
|
| 10 |
Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.[J]. European Respiratory Journal, 2008, 32(4): 924-930.
|
| 11 |
Clive AO, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis[J]. Cochrane Database of Systematic Reviews, 2016, 5(5): CD010529.
|
| 12 |
Li Q, Sun W, Yuan D, et al. Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer[J]. Thoracic Cancer, 2016, 7(1): 136-139.
|
| 13 |
向春艳，何小燕，李逐波，等. TNF-α在癌症中的作用研究进展[J]. 生命科学，2012, 24(3): 000250-000254.
|
| 14 |
Mcgrath EE. The tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL？[J]. Journal of Thoracic Oncology, 2011, 6(6): 983.
|
| 15 |
Bertazza L, Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology.[J]. Current Medicinal Chemistry, 2010, 17(29): 3337-3352.
|
| 16 |
Van HR, Ten Hagen TL, Eggermont AM. TNF-α in cancer treatment：molecular insights, antitumor effects, and clinical utility[J]. Oncologist, 2006, 11(4): 397-408.
|
| 17 |
Mocellin S, Nitti D. TNF and cancer: the two sides of the coin[J]. Frontiers in Bioscience, 2008, 13(7): 2774-2783.
|
| 18 |
Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer[J]. Frontiers in Bioscience A Journal & Virtual Library, 2008, 13(13): 5094.
|
| 19 |
Ham B, Fernandez MC, D′Costa Z, et al. The diverse roles of the TNF axis in cancer progression and metastasis[J]. Trends in Cancer Research, 2016, 11(1): 1-9.
|
| 20 |
Shen J, Xiao Z, Zhao Q, et al. Anti-cancer therapy with TNFα and IFNγ：A comprehensive review.[J]. Cell Proliferation, 2018: e12441.
|
| 21 |
Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL)：A new path to anti-cancer therapies[J]. European Journal of Pharmacology, 2009, 625(1): 63-72.
|
| 22 |
Ohtani T, Nakamura T, Toda K, et al. Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell[J]. Febs Letters, 2006, 580(6): 1597.
|
| 23 |
Zhang W, Chen Z, Li F, et al. Tumour necrosis factor-α (TNF-α) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-α[J]. Immunology, 2003, 108(2): 177-188.
|
| 24 |
Kuol N, Stojanovska L, Nurgali K, et al. PD-1/PD-L1 in disease.[J]. Immunotherapy, 2017, 10(2): 149.
|
| 25 |
Boutsikou E, Domvri K, Hardavella G, et al. Tumour necrosis factor，interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.[J]．Ther Adv Med Oncol, 2018, 10: 1-8.
|
| 26 |
Jiang C, Niu J, Li M, et al. Tumor Vasculature-Targeted Recombinant Mutated Human TNF-α Enhanced the Antitumor Activity of Doxorubicin by Increasing Tumor Vessel Permeability in Mouse Xenograft Models[J]. Plos One, 2014, 9(1): e87036.
|
| 27 |
Stathopoulos GT, Kollintza A, Moschos C, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion[J]. Cancer Research, 2007, 67(20): 9825.
|
| 28 |
Han YP, Nien YD, Garner WL. Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase[J]. J Biol Chem, 2002, 277(30): 27319-27327.
|
| 29 |
Barshishat M, Ariel A, Cahalon L, et al. TNF-alpha and IL-8 regulate the expression and function of CD44 variant proteins in human colon carcinoma cells[J]. Clinical & Experimental Metastasis, 2002, 19(4): 327-337.
|
| 30 |
Nishi E, Hiraoka Y, Yoshida K, et al. Nardilysin enhances ectodomain shedding of heparin-binding EGF-like growth factor through activation of TNF-α converting enzyme[J]. J Biol Chem, 2006, 281(41): 31164-31172.
|
| 31 |
Faurschou A. Role of tumor necrosis factor-α in the regulation of keratinocyte cell cycle and DNA repair after ultraviolet-B radiation[J]. Danish Medical Bulletin, 2010, 57(10): B4179.
|
| 32 |
Hamed EA, El-Noweihi AM, Mohamed AZ, et al. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.[J]. Respirology, 2004, 9(1): 81-86.
|
| 33 |
Li M, Wang H, Wang X, et al. Diagnostic accuracy of tumor necrosis factor-alpha, interferon-gamma, interlukine-10 and adenosine deaminase 2 in differential diagnosis between tuberculous pleural effusion and malignant pleural effusion[J]. Journal of Cardiothoracic Surgery, 2014, 9(1): 1-6.
|
| 34 |
Lejeune FJ, Rüegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.[J]. Bulletin Du Cancer, 2006, 93(8): 90-100.
|
| 35 |
Xia LM, Zhou YY. rmhTNF-α Combined with Cisplatin Inhibits Proliferation of A549 Cell Line In Vitro[J]. Chinese Medical Sciences Journal, 2014, 29(3): 185-187.
|
| 36 |
Wang H, Yan Z, Shi J, et al. Expression, purification, and characterization of a neovasculature targeted rmhTNF-alpha in Escherichia coli[J]. Protein Expression & Purification, 2006, 45(1): 60-65.
|
| 37 |
Ji W, Yuan M, Zhang L, et al. Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin[J]. Molecular Medicine Reports, 2017, 15(6): 3865.
|
| 38 |
Jiang C, Niu J, Li M, et al. Tumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models[J]. Plos One, 2014, 9(1): e87036.
|
| 39 |
Hu H, Yin J, Wang M, et al. GX1 targeting delivery of rmhTNFα evaluated using multimodality imaging[J]. International Journal of Pharmaceutics, 2014: 181-191.
|
| 40 |
Yan Z, Zhao N, Wang Z, et al. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo[J]. Cytotherapy, 2006, 8(4): 415-423.
|
| 41 |
Li M, Qin X, Xue X, et al. Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity[J]. Anticancer Drugs, 2010, 21(3): 243-251.
|
| 42 |
张伟京，克晓燕，王杰军，等. 注射用重组改构人肿瘤坏死因子-NC(rhTNF-NC)治疗恶性肿瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志，2015, 20(9): 819-824.
|
| 43 |
秦叔逵，刘秀峰，马 军，等. 注射用重组改构人肿瘤坏死因子治疗国人恶性胸、腹腔积液的前瞻性多中心临床研究[J]. 临床肿瘤学杂志，2016, 21(7): 577-584.
|
| 44 |
魏 东，汤礼军，张 伶，等. 重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析[J]. 重庆医科大学学报，2009, 34(4): 472-475.
|
| 45 |
中国临床肿瘤学会抗肿瘤药物安全管理专家委员会. 重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识[J]. 临床肿瘤学杂志，2018, 23(1): 67-72.
|
| 46 |
Liu X, Zhang XF, Zheng ZW, et al. The effect of chemotherapy combined with recombination mutant human tumor necrosis factor on advanced cancer[J]. Journal of Translational Medicine, 2004, 2(1): 33-33.
|
| 47 |
Ma X, Song Y, Zhang K, et al. Recombinant mutated human TNF in combination with chemotherapy for stage ⅢB/Ⅳ，non-small cell lung cancer: a randomized, phase Ⅲ study[J]. Sci Rep, 2015, 4: 9918.
|
| 48 |
Jin Y, Tao X, Gao Y, et al. Influence of rmhTNF on the chemotherapy treatment of small cell lung cancer[J]. Journal of Huazhong University of Science and Technology (Medical Sciences), 2006, 26(1): 40.
|
| 49 |
Li M, Xu T, Zhang Z, et al. Phase Ⅱ multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-a in combination with chemotherapies in cancer patients[J]. Cancer Science, 2012, 103(2): 288-295.
|
| 50 |
穆海玉，沈春燕，胡素萍. 重组改构人肿瘤坏死因子联合NP方案治疗晚期非小细胞肺癌的临床研究[J]. 临床肿瘤学杂志，2008, 13(10): 884-887.
|
| 51 |
张 娟，孙秋实，张凌云. 重组改构人肿瘤坏死因子联合博来霉素胸腔灌注治疗肺癌恶性胸腔积液的临床观察[J]. 临床肿瘤学杂志，2011, 16(12): 1104-1107.
|
| 52 |
李 栋，姜子瑜，张培影，等. 重组改构人肿瘤坏死因子经胸腔注射治疗恶性胸腔积液41例临床疗效研究[J]. 肿瘤药学，2016, 6(6): 456-460.
|